EDAP TMS SA current report, Q1 FY2025

EDAP TMS SA - Form 6-K Summary

Business Context and Reporting Period

EDAP TMS SA, a global leader in robotic energy-based therapies, reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2024. The filing was submitted on March 27, 2025. The company focuses on its core Focal One Robotic HIFU platform for prostate cancer treatment while expanding into endometriosis, benign prostatic hyperplasia (BPH), and pancreatic cancer.

Key Financial Metrics

Metric Q4 2024 (USD) Q4 2023 (USD) Full Year 2024 (USD) Full Year 2023 (USD)
Total Revenue $21.5 million $21.3 million $69.2 million $65.4 million
HIFU Revenue $9.3 million $8.1 million $25.7 million $22.3 million
Gross Profit $9.6 million $9.3 million $28.7 million $26.4 million
Gross Margin 44.8% 43.7% 41.4% 40.4%
Operating Loss ($4.0 million) ($3.8 million) ($22.2 million) ($21.5 million)
Net Loss ($2.1 million) ($5.5 million) ($20.5 million) ($22.9 million)
Cash & Equivalents $30.9 million (as of Dec 31, 2024)

Liquidity and Debt: As of December 31, 2024, the company held cash and cash equivalents of EUR 29.8 million ($30.9 million), a decrease from EUR 43.5 million ($48.1 million) in 2023. Short-term borrowings increased to EUR 6.2 million ($6.5 million) from EUR 2.5 million ($2.7 million) in the prior year. Long-term debt remained relatively stable at EUR 2.2 million ($2.2 million).

Material Changes vs. Prior Period

  • Revenue Growth: Full-year revenue increased 6.1% year-over-year, driven primarily by a 15.7% increase in HIFU revenue. Q4 revenue grew 3.6% year-over-year.
  • HIFU Segment Performance: Q4 HIFU revenue reached a record $9.3 million, up 15.0% from Q4 2023. The company sold 11 Focal One systems in Q4 2024 versus 10 in Q4 2023. U.S. Focal One procedures grew 51% year-over-year in 2024.
  • Profitability: Net loss improved significantly in Q4 2024 ($2.1 million) compared to Q4 2023 ($5.5 million), aided by a favorable currency exchange gain of $1.8 million in Q4 2024 versus a loss of $1.6 million in Q4 2023. Full-year net loss narrowed to $20.5 million from $22.9 million.
  • Segment Mix: Distribution revenue declined 7.5% in Q4 2024 due to product mix, while LITHO revenue increased 4.3% driven by unit sales.

Guidance, Outlook, and Management Commentary

Management highlighted strong momentum in the core Focal One business, citing record quarterly sales and the publication of the landmark HIFI study in European Urology, which demonstrated positive outcomes for HIFU versus surgery in prostate cancer. The company expects to have its largest presence at the American Urology Association (AUA) Meeting in April 2025.

Clinical and Regulatory Milestones:

  • CE Mark: Received CE Mark for Focal One for the treatment of deep infiltrating endometriosis (March 2025).
  • Reimbursement: CMS finalized a 2025 Medicare Hospital payment rate of $9,247 for HIFU procedures, a 5.4% increase over 2024, supporting the economic case for hospital adoption.
  • Clinical Trials: First patients treated in Phase I/II studies for pancreatic cancer (PULS Trial) and Benign Prostatic Hyperplasia (BPH).
  • Technology: Successful completion of the first OnQ Prostate-assisted Focal One procedure using Restriction Spectrum Imaging (RSI) technology.

Risks: Forward-looking statements are subject to risks including clinical status and market acceptance of HIFU devices, global economic instability, inflation, and geopolitical factors.

Investor Verification Checklist

  • Cash Burn Rate: Verify the sustainability of the cash position ($30.9 million) given the operating loss of $22.2 million and negative operating cash flow of $14.7 million for the full year 2024.
  • HIFU Adoption Metrics: Confirm the trajectory of U.S. procedure volume growth (reported 51% YoY) and system sales to validate the "mainstream treatment" narrative.
  • Reimbursement Impact: Assess the actual uptake of the new 2025 CMS reimbursement rates ($9,247) and their effect on hospital purchasing decisions.
  • Currency Sensitivity: Note the significant impact of currency exchange gains/losses on net income (e.g., $1.8M gain in Q4 2024 vs. $1.6M loss in Q4 2023) and monitor future FX exposure.
  • Debt Structure: Review the increase in short-term borrowings (from $2.7M to $6.5M) and the terms associated with these liabilities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.